INTRODUCTION Human papillomaviruses (HPV) are DNA viruses with a double strand of
DNA that belong to the family Papovaviridae. 1 Currently, nearly 200 HPV types have been …

Oncogenic human papillomavirus (HPV) infection is the cause of nearly all cervical cancers
and a proportion of other anogenital and oropharyngeal cancers. A bivalent vaccine …

Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …

A global strategy aimed at eliminating cervical cancer by 2030 was released by WHO and
was recently adopted by many countries and partners. However, few diseases reflect global …

Globally, cervical cancer remains a public health issue of increasing concern that could be
addressed through the implementation of effective preventive measures such as human …

Cervical cancer is the second leading cause of cancer deaths among women in the world
and more than 85% of cervical cancer cases occur in women living in developing countries …

Cervical cancer is estimated to cause 341,831 deaths each year, with 9 of 10 deaths
occurring in developing countries. Over the past decade, there has been a significant …

Introduction Widespread adoption of the human papillomavirus (HPV) vaccine will require
population acceptance and tailoring of immunisation services to community needs and …

Almost all cases of cervical cancer are caused by human papillomavirus (HPV). China
accounts for about a third of the global burden of cervical cancer, with about 98 900 new …

Ten years after the first licencing of a prophylactic human papillomavirus (HPV) vaccine, this
paper reviews global information on programme coverage, as reported to WHO and from the …